116 related articles for article (PubMed ID: 10861754)
1. Pharmacodynamic model of testosterone suppression after intramuscular depot estrogen therapy in prostate cancer.
Johansson CJ; Gunnarsson PO
Prostate; 2000 Jun; 44(1):26-30. PubMed ID: 10861754
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and testosterone suppression of a single dose of polyestradiol phosphate (Estradurin) in prostatic cancer patients.
Stege R; Gunnarsson PO; Johansson CJ; Olsson P; Pousette A; Carlström K
Prostate; 1996 May; 28(5):307-10. PubMed ID: 8610057
[TBL] [Abstract][Full Text] [Related]
3. Single drug polyestradiol phosphate therapy in prostatic cancer.
Stege R; Carlström K; Collste L; Eriksson A; Henriksson P; Pousette A
Am J Clin Oncol; 1988; 11 Suppl 2():S101-3. PubMed ID: 3242384
[TBL] [Abstract][Full Text] [Related]
4. Time for revival of estrogens in the treatment of advanced prostatic carcinoma? Pharmacokinetics, and endocrine and clinical effects, of a parenteral estrogen regimen.
Henriksson P; Carlström K; Pousette A; Gunnarsson PO; Johansson CJ; Eriksson B; Altersgård-Brorsson AK; Nordle O; Stege R
Prostate; 1999 Jul; 40(2):76-82. PubMed ID: 10386467
[TBL] [Abstract][Full Text] [Related]
5. Adrenocortical function in prostatic cancer patients: effects of orchidectomy or different modes of estrogen treatment on basal steroid levels and on the response to exogenous adrenocorticotropic hormone.
Carlström K; Stege R
Urol Int; 1990; 45(3):160-3. PubMed ID: 2161578
[TBL] [Abstract][Full Text] [Related]
6. Possible bone-preserving capacity of high-dose intramuscular depot estrogen as compared to orchidectomy in the treatment of patients with prostatic carcinoma.
Carlström K; Stege R; Henriksson P; Grande M; Gunnarsson PO; Pousette A
Prostate; 1997 May; 31(3):193-7. PubMed ID: 9167772
[TBL] [Abstract][Full Text] [Related]
7. Plasma concentrations of estradiol and testosterone in single-drug polyestradiol phosphate therapy for prostatic cancer.
Norlén BJ; Fritjofsson A; Grönquist L; Gunnarsson PO; Johansson SA; Plym-Forshell G
Eur Urol; 1987; 13(3):193-7. PubMed ID: 3609099
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacology of polyestradiol phosphate.
Gunnarsson PO; Norlén BJ
Prostate; 1988; 13(4):299-304. PubMed ID: 3217277
[TBL] [Abstract][Full Text] [Related]
9. Hormonal regulation of serum lipoprotein (a) levels: effects of parenteral administration of estrogen or testosterone in males.
Berglund L; Carlström K; Stege R; Gottlieb C; Eriksson M; Angelin B; Henriksson P
J Clin Endocrinol Metab; 1996 Jul; 81(7):2633-7. PubMed ID: 8675589
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular follow-up of patients with prostatic cancer treated with single-drug polyestradiol phosphate.
Henriksson P; Eriksson A; Stege R; Collste L; Pousette A; von Schoultz B; Carlström K
Prostate; 1988; 13(3):257-61. PubMed ID: 3211807
[TBL] [Abstract][Full Text] [Related]
11. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study.
Hedlund PO; Henriksson P
Urology; 2000 Mar; 55(3):328-33. PubMed ID: 10699602
[TBL] [Abstract][Full Text] [Related]
12. Single-drug parenteral estrogen treatment in prostatic cancer: a study of two maintenance-dose regimens.
Stege R; Carlström K; Collste L; Eriksson A; Henriksson P; Pousette A; von Schoultz B
Prostate; 1989; 14(2):183-8. PubMed ID: 2710692
[TBL] [Abstract][Full Text] [Related]
13. Effects of orchidectomy and different modes of high dose estrogen treatment on circulating "free" and total 1,25-dihydroxyvitamin D in patients with prostatic cancer.
Hagenfeldt Y; Carlström K; Berlin T; Stege R
J Steroid Biochem Mol Biol; 1991 Aug; 39(2):155-9. PubMed ID: 1888674
[TBL] [Abstract][Full Text] [Related]
14. Effects of orchiectomy and polyestradiol phosphate therapy on serum lipoprotein lipids and glucose tolerance in prostatic cancer patients.
Aro J; Haapiainen R; Sane T; Rannikko S; Pelkonen R; Alfthan O
Eur Urol; 1990; 17(3):229-35. PubMed ID: 2351192
[TBL] [Abstract][Full Text] [Related]
15. Polyestradiol phosphate and ethinyl estradiol in treatment of prostatic carcinoma.
Lindstedt E
Scand J Urol Nephrol Suppl; 1980; 55():95-7. PubMed ID: 6938044
[TBL] [Abstract][Full Text] [Related]
16. Polyestradiol phosphate (160 mg/month) or LHRH analog (buserelin depot) in the treatment of locally advanced or metastasized prostatic cancer. The Finnprostate Group.
Aro J; Ruutu M; Juusela H; Hansson E; Permi J
Ann Chir Gynaecol Suppl; 1993; 206():5-8. PubMed ID: 8291869
[TBL] [Abstract][Full Text] [Related]
17. Immediate estrogen or estramustine phosphate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer: a randomized multicenter study with 15 years of followup. The South Sweden Prostate Cancer Study Group.
Lundgren R; Nordle O; Josefsson K
J Urol; 1995 May; 153(5):1580-6. PubMed ID: 7714978
[TBL] [Abstract][Full Text] [Related]
18. Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate.
Spetz AC; Hammar M; Lindberg B; Spångberg A; Varenhorst E;
J Urol; 2001 Aug; 166(2):517-20. PubMed ID: 11458057
[TBL] [Abstract][Full Text] [Related]
19. The effects of a brain-enhanced estradiol delivery system on testosterone and androgen-dependent tissues. I. Dose-response and time-course evaluation.
Rahimy MH; Anderson WR; Brewster ME; Bodor N; Simpkins JW
Endocrinology; 1991 Aug; 129(2):717-25. PubMed ID: 1855469
[TBL] [Abstract][Full Text] [Related]
20. Effect of parenteral oestrogen on the coagulation system in patients with prostatic carcinoma.
Henriksson P; Blombäck M; Eriksson A; Stege R; Carlström K
Br J Urol; 1990 Mar; 65(3):282-5. PubMed ID: 2110842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
